Sumatriptan transdermal - Teva

Drug Profile

Sumatriptan transdermal - Teva

Alternative Names: NP 101; Sumatriptan iontophoretic transdermal patch; Sumatriptan iontophoretic transdermal system; Zecuity; Zelrix

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NuPathe
  • Developer NuPathe; Teva Pharmaceutical Industries
  • Class Antimigraines; Indoles; Small molecules; Sulfonamides; Tryptamines
  • Mechanism of Action Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Migraine

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Migraine(In adolescents) in USA (Transdermal, Patch)
  • 13 Jun 2016 Teva announces voluntary suspension of marketing for Zecuity® in USA
  • 01 Sep 2015 Launched for Migraine in USA (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top